Keytruda Archives - Onco'Zine

Home Tags Keytruda

Attendees during the day at the American Society of Clinical Oncology (ASCO) Courtesy: ? ASCO/Scott Morgan.

Cabozantinib + Pembrolizumab Shows ORR of 54% in Treatment of Recurrent or...

Danielle Garcia - June 4, 2022

Combination Trials with Immune Checkpoint Inhibitors may not Result in Synergistic...

Editorial Team - February 28, 2022

Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Pembrolizumab Shows Significantly Prolonged Event-free Survival in High-Risk Early-Stage TNBC

Editorial Team - February 9, 2022

KEYNOTE-122: Pembrolizumab vs Chemotherapy in Platinum-Pretreated Nasopharyngeal Carcinoma

Editorial Team - September 20, 2021

Immunotherapy After Surgery Extends Disease-Free Survival for Select Patients With Kidney...

Editorial Team - June 7, 2021

General view of the 55th Annual Meeting of the American Society of Oncology (ASCO). Courtesey: 2019 ? ASCO/Kristen Norman 2019.

Comprehensive Genomic and Transcriptomic Profiling Predicts Pan-Tumor Benefit of Pembrolizumab

Editorial Team - June 5, 2021

$FDA Approves Pembrolizumab in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma$

FDA Approves Pembrolizumab in Adult Patients With Relapsed or Refractory Classical...

Editorial Team - October 15, 2020

ESMO 2020: First-in-class MK-4830 Antibody Targeting ILT4 Shows Promising Preliminary...

Editorial Team - September 20, 2020

Seattle Genetics. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO). In the back of the booth the enfortumab vedotin presentation.

Potential Accelerated Approval Enfortumab Vedotin + Pembrolizumab in Metastatic Urothelial Cancer

Peter Hofland, Ph.D - April 2, 2020

Combination Enfortumab Vedotin + Pembrolizumab Granted Breakthrough Therapy in Bladder Cancer

Peter Hofland, Ph.D - February 19, 2020

12 3 Page 1 of 3

LATEST NEWS

Study: Blocking Immune Suppressor Cells in Mice with Glioblastoma Improves Survival

Danielle Garcia - January 27, 2023

Stephen Spellman: Mismatched Unrelated Donors – Key to Erasing the Gap in Donor Availability...

Editorial Team - January 18, 2023

New Technologies in Post-surgical Wound Dressings

Brad Greer, JD - January 16, 2023

The Patient Journey Tech Stack: 10 Predictions for 2023

Yishai Knobel - January 16, 2023

Study Confirms: ‘Extreme Lack of Consistency’ Hampers the Potential of Nanosized Medicines

Danielle Garcia - January 12, 2023

Press Releases | Cancer

Java Original Coffee Company to Support The Onco’Zine Brief Radio... January 25, 2023
The Java Original Coffee Company, the home of incredible artisan roasted gourmet coffee, is committed to support the cancer research community as well as select individuals and organizations involved...(PRWeb January 25, 2023)Read the full story at https://www.prweb.com/releases/java_original_coffee_company_to_support_the_oncozine_brief_radio_broadcast_and_podcast/prweb19133000.htm
GO2 for Lung Cancer Addresses Disparities and Health Inequities... January 23, 2023
Through efforts in awareness, education and readily available resources, GO2 for Lung Cancer is helping underserved communities access information and education needed to increase survival rates.(PRWeb January 23, 2023)Read the full story at https://www.prweb.com/releases/go2_for_lung_cancer_addresses_disparities_and_health_inequities_head_on_in_underserved_communities/prweb19126525.htm
$1.3 Billion Liquid Biopsy Market the Present and Future of Clinical... January 20, 2023
Dramatic changes have occurred in the global liquid biopsy market that continue to impact how medical professionals diagnosis, treat, and monitor cancer.(PRWeb January 20, 2023)Read the full story at https://www.prweb.com/releases/1_3_billion_liquid_biopsy_market_the_present_and_future_of_clinical_oncology/prweb19123773.htm